Fate Therapeutics vs TScan Therapeutics
FATE and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FATE and TCRX compare
Fate Therapeutics is the larger company, worth 14 times as much as TScan Therapeutics ($153M against $10.9M).
Fate Therapeutics grew revenue faster over the last twelve months (−33.4% versus −38.4% for TScan Therapeutics).
TScan Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2219% compared with −2620% at Fate Therapeutics.
Fate Therapeutics scores higher on the StockData Score (6 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FATE | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | $153M | $10.9M |
| Share price | $1.28 | $0.161 |
| Change, 1 year | 23.1% | −86.5% |
| Change, 5 years | −97.7% | −98.2% |
| Beta (5Y) | 2.42 | 0.92 |
| Employees | 161 | 142 |
| StockData Score | ||
| Total score | 6 (better) | 4 |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 32.3× | 2.1× (better) |
| P/B | 1.2× | 0.3× (better) |
| FCF yield | −69.7% (better) | −1026% |
| Fair value | $1.10 | $0.823 |
| Margin of safety | −16.5% | 80.5% (better) |
| Growth | ||
| Revenue growth (TTM) | −33.4% (better) | −38.4% |
| Revenue growth, 5Y average | −26.7% | 56.9% (better) |
| Profitability | ||
| Operating margin | −2760% | −2247% (better) |
| Net margin | −2620% | −2219% (better) |
| FCF margin | −2249% | −2153% (better) |
| Return on equity | −67.8% (better) | −126% |
| Return on invested capital | −1647% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.87 (better) |
| Interest coverage | – | −40.7× |
| Current ratio | 4.41 (better) | 2.03 |
| Altman Z-score | −9.92 | −8.20 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 59.9% | 53.5% |
| Held by insiders | 25.7% | 32.8% |
| Insider net buying, 12 months | −$336K | $146K (better) |
| Short interest, % of float | 11.2% | 4.4% |
Go deeper
- FATE stock overview
- FATE income statement
- FATE valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.